Cancer Therapy's Hidden Reliance on Fragile Isotope Supply

A convergence of geopolitical pressures is straining the supply chain behind one of oncology's fastest-growing fields, radioligand therapy. These treatments inject radioactive isotopes that travel through the body to target and destroy cancer cells. The segment sits inside the roughly 280 billion dollar global cancer-treatment market. As of June 2026 the radiopharmaceutical corner is valued at around 30 billion dollars and is expanding quickly, yet its raw material base depends on a small number of nuclear reactors, rare earth supplies, and isotope producers concentrated in regions exposed to conflict and export controls.

Two isotopes sit at the center of the industry.

Lutetium-177, a rare earth element, powers the Novartis blockbuster drugs Lutathera and Pluvicto, which together generated about 2.8 billion dollars in sales in 2025. It is made in nuclear research reactors using enriched targets and irradiation cycles that last weeks.

Actinium-225, an alpha emitter widely seen as the next breakthrough, remains in extremely short supply, with global clinical output still measured in a very small number of curies per year.

The Russia-Ukraine war is the first pressure point. Russia historically supplied a meaningful share of medical isotopes and enriched targets. Although these materials are exempt from sanctions, financial and logistical barriers since the 2022 invasion have pushed Western producers to diversify. ITM, a major German isotope producer based near Munich, moved its supply toward a North American source several years ago and has said the war accelerated that shift to reduce exposure to a partner whose access can change with politics.

China's grip on rare earths is the second pressure point. The country controls a dominant share of global rare earth processing, and lutetium falls within that category. In October 2025 Beijing added ytterbium to its list of rare earths subject to export controls (ytterbium-176 is the raw material used to produce lutetium-177). Implementation has been suspended until November 2026, but the decision has added uncertainty. China is also now asking buyers for detailed information in export license applications, which producers worry could expose sensitive commercial data even if medical exemptions remain in place.

The third pressure point is Iran. The 2025 conflict involving Iran and renewed tension around the Strait of Hormuz in 2026 prompted several drug developers to stockpile raw materials. Companies have reordered inputs such as helium, which is used in isotope production, to guard against possible disruption to shipping and energy flows in the region.

The strain is not only a future risk. Actinium-225 has been in short supply through 2025 and into 2026, and at least one developer paused a late-stage trial because it could not secure enough of the isotope. Earlier, Pluvicto landed on the United States Food and Drug Administration shortage list in early 2023 after demand outpaced output from a single manufacturing site in Italy, before extra capacity came online. The short half-lives of these isotopes, about six and a half days for lutetium-177 and under ten days for actinium-225, mean doses cannot be stored. They must reach patients within days of production.

Producers and drugmakers are now racing to build resilience. In March 2026 TerraPower Isotopes announced a 450 million dollar actinium-225 plant in Philadelphia that, combined with its Washington state site, is expected to lift capacity twentyfold when it opens around 2029. Belgian producer PanTera raised about 140 million dollars in 2025 to scale actinium-225 output. ITM, Eckert and Ziegler, Niowave, and others have signed multiyear supply deals with Novartis, AstraZeneca, and additional partners. New production routes, including radium-226 proton irradiation and accelerator-based methods, are under evaluation to ease the bottleneck.

For now treatment continues and the leading drugs remain available, but the structural dependency persists. Demand for actinium-225 alone could rise severalfold by the end of the decade, far ahead of current capacity. Until new facilities come online and supply sources diversify, the radiopharmaceutical industry stays exposed to any escalation in the conflicts and trade restrictions that shape access to its core materials. The situation is active and evolving, with no near-term resolution expected.